All stock lists
Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
Healthcare · Biotechnology
10.89+0.32 (+3.03%)
Insider Score
––Not scored
VIR Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
VIR analyst forecast
VIR analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
VIR 12-month price target
$22.00+102.0% upsideaverage of 1 firm
$22.00High
$22.00Low
Best analysts covering VIR
- Morgan Stanley67%success rate · 3 calls
- Needham38%success rate · 16 calls
- Barclays25%success rate · 4 calls
- HC Wainwright & Co.20%success rate · 20 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
VIR analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-07 |
| H.C. Wainwright | — | $22.00 | +88.3% | — | 2026-10-07 | |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-06-11 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-06-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-04 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-02-25 |
| — | Needham | Buy | — | — | Reiterated | 2026-02-24 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-02-24 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-02-24 |
| — | Needham | Buy | — | — | Reiterated | 2026-02-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-12-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-15 |
| — | B of A Securities | Buy | — | — | Upgraded | 2025-08-27 |
| — | Needham | Buy | — | — | Reiterated | 2025-05-22 |
| — | Needham | Buy | — | — | Reiterated | 2025-05-12 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-04-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-28 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-02-28 |
| — | Needham | Buy | — | — | Reiterated | 2025-02-27 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-31 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2025-01-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-10 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2025-01-09 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2025-01-09 |
| — | Needham | Buy | — | — | Reiterated | 2024-11-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-04 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-11-04 |
| — | Needham | Buy | — | — | Reiterated | 2024-11-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-20 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-08-02 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2024-06-06 |
| — | Needham | Buy | — | — | Reiterated | 2024-06-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-06-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-07 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2024-05-03 |
| — | Needham | Buy | — | — | Reiterated | 2024-05-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-15 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2024-02-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-02-14 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2024-01-29 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-01-23 |
| — | Needham | Buy | — | — | Reiterated | 2023-11-03 |
| — | B of A Securities | Neutral | — | — | Downgraded | 2023-09-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-07 |
| — | Needham | Buy | — | — | Reiterated | 2023-08-04 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-07-21 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2023-07-21 |
| — | Barclays | Overweight | — | — | Reiterated | 2023-07-21 |
| — | Needham | Buy | — | — | Reiterated | 2023-07-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-07-20 |
| — | Needham | Buy | — | — | Reiterated | 2023-05-05 |
| — | Needham | Buy | — | — | Reiterated | 2023-04-19 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2023-04-04 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2023-03-06 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-03-06 |
| — | Needham | Buy | — | — | Reiterated | 2023-02-24 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2023-02-23 |
| — | Goldman Sachs | Buy | — | — | Upgraded | 2023-02-21 |
VIR earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-23 | -0.42 | -0.31 | $19.9M | $64.1M |
| 2026-05-06 | -0.01 | -0.85 | $55.5M | $-29K |
| 2026-08-05 | 0.33 | 0.47 | $135.9M | $238.9M |
| 2026-11-04 | -0.74 | 0.00 | $859K | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.